Matt Outten MBA, Alm, Cpc
About Matt Outten MBA, Alm, Cpc
Matt Outten is the Chief Executive Officer at QED Therapeutics Oncology and the Chief Commercial Officer at BridgeBio, where he has worked since 2019. He has extensive experience in the pharmaceutical industry, having held various leadership roles at notable companies and possessing expertise in market access strategies and pharmacoeconomic modeling.
Work at BridgeBio
Matt Outten serves as the Chief Executive Officer at QED Therapeutics Oncology and the Chief Commercial Officer at BridgeBio. He has held these positions since 2019, contributing to the company's focus on developing innovative therapies in the oncology sector. His leadership in these roles emphasizes strategic planning and market access, which are critical for the success of specialized medications.
Education and Expertise
Matt Outten holds an MBA from the University of Delaware, where he studied Management. He also earned a Master of Liberal Arts in Extension Studies from Harvard University, focusing on International Relations. Additionally, he has a Bachelor of Arts in Psychology from Hamilton College. His educational background supports his expertise in pharmacoeconomic modeling and strategic planning in the pharmaceutical industry.
Background
Matt Outten has a diverse professional background in the pharmaceutical industry, with experience spanning over two decades. He has worked in various roles, including sales, marketing, and market access. His career includes significant positions at companies such as Schering-Plough, GSK, and Pharmacyclics, where he developed skills in managing multimillion-dollar budgets and leading commercial operations.
Achievements
Throughout his career, Matt Outten has led initiatives in forming specialty pharmacy and distributor networks, which are essential for the distribution of specialized medications. He has played a significant role in strategic alliances and co-promotion efforts, enhancing collaborative opportunities within the industry. His work includes structuring and negotiating rebates and pricing, as well as creating patient assistance programs to improve medication access for patients.